314 related articles for article (PubMed ID: 23665966)
1. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis.
Singh S; Khanna S; Pardi DS; Loftus EV; Talwalkar JA
Inflamm Bowel Dis; 2013 Jul; 19(8):1631-8. PubMed ID: 23665966
[TBL] [Abstract][Full Text] [Related]
2. High dose ursodeoxycholic acid in primary sclerosing cholangitis does not prevent colorectal neoplasia.
Lindström L; Boberg KM; Wikman O; Friis-Liby I; Hultcrantz R; Prytz H; Sandberg-Gertzén H; Sangfelt P; Rydning A; Folvik G; Gangsøy-Kristiansen M; Danielsson A; Bergquist A
Aliment Pharmacol Ther; 2012 Feb; 35(4):451-7. PubMed ID: 22221173
[TBL] [Abstract][Full Text] [Related]
3. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
[TBL] [Abstract][Full Text] [Related]
4. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.
Eaton JE; Silveira MG; Pardi DS; Sinakos E; Kowdley KV; Luketic VA; Harrison ME; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Lindor KD
Am J Gastroenterol; 2011 Sep; 106(9):1638-45. PubMed ID: 21556038
[TBL] [Abstract][Full Text] [Related]
5. Colorectal neoplasia in patients with primary sclerosing cholangitis undergoing liver transplantation: a Nordic multicenter study.
Jørgensen KK; Lindström L; Cvancarova M; Castedal M; Friman S; Schrumpf E; Foss A; Isoniemi H; Nordin A; Holte K; Rasmussen A; Bergquist A; Vatn MH; Boberg KM
Scand J Gastroenterol; 2012 Sep; 47(8-9):1021-9. PubMed ID: 22577871
[TBL] [Abstract][Full Text] [Related]
6. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis of 16 observational studies.
Zheng HH; Jiang XL
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):383-90. PubMed ID: 26938805
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholic acid treatment in IBD-patients with colorectal dysplasia and/or DNA-aneuploidy: a prospective, double-blind, randomized controlled pilot study.
Sjöqvist U; Tribukait B; Ost A; Einarsson C; Oxelmark L; Löfberg R
Anticancer Res; 2004; 24(5B):3121-7. PubMed ID: 15510599
[TBL] [Abstract][Full Text] [Related]
8. Ursodiol and colorectal cancer or dysplasia risk in primary sclerosing cholangitis and inflammatory bowel disease: a meta-analysis.
Hansen JD; Kumar S; Lo WK; Poulsen DM; Halai UA; Tater KC
Dig Dis Sci; 2013 Nov; 58(11):3079-87. PubMed ID: 23896754
[TBL] [Abstract][Full Text] [Related]
9. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.
Wang R; Leong RW
World J Gastroenterol; 2014 Jul; 20(27):8783-9. PubMed ID: 25083052
[TBL] [Abstract][Full Text] [Related]
10. Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.
Torres J; Pineton de Chambrun G; Itzkowitz S; Sachar DB; Colombel JF
Aliment Pharmacol Ther; 2011 Sep; 34(5):497-508. PubMed ID: 21692821
[TBL] [Abstract][Full Text] [Related]
11. Novel developments in IBD-related sclerosing cholangitis.
Ponsioen CY
Best Pract Res Clin Gastroenterol; 2011 Apr; 25 Suppl 1():S15-8. PubMed ID: 21640925
[TBL] [Abstract][Full Text] [Related]
12. Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
Rao BB; Lashner B; Kowdley KV
Inflamm Bowel Dis; 2018 Jan; 24(2):269-276. PubMed ID: 29361103
[TBL] [Abstract][Full Text] [Related]
13. High Risk of Advanced Colorectal Neoplasia in Patients With Primary Sclerosing Cholangitis Associated With Inflammatory Bowel Disease.
Shah SC; Ten Hove JR; Castaneda D; Palmela C; Mooiweer E; Colombel JF; Harpaz N; Ullman TA; van Bodegraven AA; Jansen JM; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; van der Woude CJ; Oldenburg B; Itzkowitz SH; Torres J
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1106-1113.e3. PubMed ID: 29378311
[TBL] [Abstract][Full Text] [Related]
14. Urosdeoxycholic acid in primary sclerosing cholangitis: a meta-analysis and systematic review.
Othman MO; Dunkelberg J; Roy PK
Arab J Gastroenterol; 2012 Sep; 13(3):103-10. PubMed ID: 23122450
[TBL] [Abstract][Full Text] [Related]
15. Increased Risk of Non-conventional and Invisible Dysplasias in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease.
Zhang R; Lauwers GY; Choi WT
J Crohns Colitis; 2022 Dec; 16(12):1825-1834. PubMed ID: 35771958
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.
Pardi DS; Loftus EV; Kremers WK; Keach J; Lindor KD
Gastroenterology; 2003 Apr; 124(4):889-93. PubMed ID: 12671884
[TBL] [Abstract][Full Text] [Related]
17. Recent insights in primary sclerosing cholangitis.
Ponsioen CY
J Dig Dis; 2012 Jul; 13(7):337-41. PubMed ID: 22713082
[TBL] [Abstract][Full Text] [Related]
18. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons.
Carey EJ; Lindor KD
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S61-4. PubMed ID: 23141896
[TBL] [Abstract][Full Text] [Related]
20. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
Rossi RE; Conte D; Massironi S
Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):123-31. PubMed ID: 26636407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
